These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 20856685)

  • 21. Oral disease-modifying therapies for multiple sclerosis.
    Kim W; Zandoná ME; Kim SH; Kim HJ
    J Clin Neurol; 2015 Jan; 11(1):9-19. PubMed ID: 25628732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
    Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
    Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods].
    Meuth SG; Ruck T; Aktas O; Hartung HP
    Nervenarzt; 2018 Aug; 89(8):895-907. PubMed ID: 29523912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in oral immunomodulating therapies in relapsing multiple sclerosis.
    Derfuss T; Mehling M; Papadopoulou A; Bar-Or A; Cohen JA; Kappos L
    Lancet Neurol; 2020 Apr; 19(4):336-347. PubMed ID: 32059809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
    Gold R
    CNS Drugs; 2011 Jan; 25(1):37-52. PubMed ID: 21128693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral disease-modifying treatments for multiple sclerosis: the story so far.
    Kieseier BC; Wiendl H
    CNS Drugs; 2007; 21(6):483-502. PubMed ID: 17521228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis.
    Mankinen P; Lundström T; Soini E; Sumelahti ML; Ruutiainen J; Niskala U; Järvinen E
    Adv Ther; 2020 Feb; 37(2):800-818. PubMed ID: 31873868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunological consequences of "immune reconstitution therapy" in multiple sclerosis: A systematic review.
    Sellner J; Rommer PS
    Autoimmun Rev; 2020 Apr; 19(4):102492. PubMed ID: 32062028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of oral immunomodulatory agents in the management of multiple sclerosis.
    Nicholas R; Giannetti P; Alsanousi A; Friede T; Muraro PA
    Drug Des Devel Ther; 2011; 5():255-74. PubMed ID: 21625416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging oral agents for multiple sclerosis.
    Fox EJ
    Am J Manag Care; 2010 Sep; 16(8 Suppl):S219-26. PubMed ID: 20873946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
    Pinheiro B; Guerreiro R; Costa J; Miguel LS
    J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
    [No Abstract]   [Full Text] [Related]  

  • 32. Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod.
    Gasperini C; Ruggieri S; Mancinelli CR; Pozzilli C
    Ther Clin Risk Manag; 2013; 9():73-85. PubMed ID: 23483794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
    Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
    Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study).
    Maltby VE; Lea RA; Monif M; Fabis-Pedrini MJ; Buzzard K; Kalincik T; Kermode AG; Taylor B; Hodgkinson S; McCombe P; Butzkueven H; Barnett M; Lechner-Scott J
    JMIR Res Protoc; 2021 Oct; 10(10):e24969. PubMed ID: 34665152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral Cladribine in Patients who Change From First-Line Disease Modifying Treatments for Multiple Sclerosis: Protocol of a Prospective Effectiveness and Safety Study (CLAD CROSS).
    Tsivgoulis G; Deftereos S; Gobbi C; Gulowsen Celius E; Kulakowska A; Maniscalco G; Mendes I; Grigoriadis N
    J Cent Nerv Syst Dis; 2022; 14():11795735211069441. PubMed ID: 35392050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis.
    Paolicelli D; Manni A; Iaffaldano A; Trojano M
    CNS Drugs; 2020 Jan; 34(1):65-92. PubMed ID: 31898276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential mechanisms of action related to the efficacy and safety of cladribine.
    Baker D; Pryce G; Herrod SS; Schmierer K
    Mult Scler Relat Disord; 2019 May; 30():176-186. PubMed ID: 30785074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cladribine tablets' potential role as a key example of selective immune reconstitution therapy in multiple sclerosis.
    Boyko AN; Boyko OV
    Degener Neurol Neuromuscul Dis; 2018; 8():35-44. PubMed ID: 30050387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets.
    Gold R; Fätkenheuer G; Hartung HP; Kleinschnitz C; Marks R; Maschke M; Bayas A; Löbermann M; Zettl UK; Wiendl H
    Ther Adv Neurol Disord; 2021; 14():17562864211019598. PubMed ID: 34671422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
    Cook S; Leist T; Comi G; Montalban X; Giovannoni G; Nolting A; Hicking C; Galazka A; Sylvester E
    Mult Scler Relat Disord; 2019 Apr; 29():157-167. PubMed ID: 30885374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.